The additive role of angiogenic markers for women with confirmed preeclampsia
American Journal of Obstetrics and Gynecology · 2023-05 · 228 (5) · 573.e1-573.e11
DOI: 10.1016/j.ajog.2022.10.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Obstetrics and Gynecology, 2023-05. Verfasst von Sunitha Suresh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago Medicine, IL. Hauptthemen laut MEDLINE: Pre-Eclampsia, Hypertension. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Siemens, Beckman Coulter Foundation, Roche.
Abstract (Originalsprache)
BACKGROUND: Hypertension complicates 2% to 8% of all pregnancies and is a leading cause of maternal and perinatal morbidity and mortality globally. Given the prognostic role that angiogenic markers play in evaluation of patients with "suspected preeclampsia," the International Society for the Study of Hypertension in Pregnancy incorporated angiogenic imbalance into the 2021 definition of preeclampsia. As women with "suspected preeclampsia" are a heterogeneous group, with some already meeting the diagnostic criteria for preeclampsia, we evaluated whether the soluble fms-like tyrosine kinase-1/placental growth factor ratio adds prognostic value among these women. OBJECTIVE: This study aimed to assess the additive value of soluble fms-like tyrosine kinase-1/placental growth factor ratio when the diagnostic criteria for preeclampsia have already been met. STUDY DESIGN: This was a secondary analysis of a prospective cohort study of patients presenting to obstetrical triage with suspected preeclampsia at ≥20+0 weeks' gestation from July 2009 to June 2012 in Boston, United States. Clinicians were masked to soluble fms-like tyrosine kinase-1/placental growth factor ratio results. Clinical records were reviewed for maternal and neonatal care and outcomes. The value of the soluble fms-like tyrosine kinase-1/placental growth factor ratio (≤38, >38, or >85) was assessed for identifying women at low or high risk of evolving into preeclampsia with severe features within 2 weeks of the triage visit, with preeclampsia with severe features being defined by the American College of Obstetricians and Gynecologists (2013 definition). Based on information in obstetrical triage, preeclampsia among triage patients was defined either by: (1) The International Society for the Study of Hypertension in Pregnancy "restrictive" criteria (ie, new-onset hypertension and proteinuria at ≥20 weeks), or (2) The International Society for the Study of Hypertension in Pregnancy "broad" maternal criteria (ie, new-onset hypertension with proteinuria or one/more relevant maternal end-organ complications). RESULTS: Of 1043 patients included, 459 presented at 20+0 to 34+6 weeks and 584 at ≥35+0 weeks. In triage, 25.8% of women with "suspected preeclampsia" already met the preeclampsia criteria based on the International Society for the Study of Hypertension in Pregnancy broad criteria and 22.0% based on the restrictive criteria. In separate multivariable analyses adjusted for gestational age, a soluble fms-like tyrosine kinase-1/placental growth factor ratio >38 was independently associated with preeclampsia with severe features within 2 weeks even after adjusting for preeclampsia diagnosis in obstetrical triage, whether that preeclampsia were defined restrictively (odds ratio, 15.62; 95% confidence interval, 8.91-27.40) or broadly (odds ratio, 14.56; 95% confidence interval, 8.30-25.56). A soluble fms-like tyrosine kinase-1/placental growth factor ratio ≤38 was good at ruling out development of preeclampsia with severe features within 2 weeks among all patients and among those meeting the restrictive or broad definitions of preeclampsia (negative likelihood ratios, ≤0.16), driven by performance of the ratio before 35 weeks (ie, negative likelihood ratio ≤0.12). A soluble fms-like tyrosine kinase-1/placental growth factor ratio >85 was good at ruling-in preeclampsia with severe features within 2 weeks among women with suspected preeclampsia, either before (positive likelihood ratio, 8.20) or after 35 weeks (positive likelihood ratio, 6.00) and fair at ruling-in preeclampsia with severe features within 2 weeks when preeclampsia had already been confirmed in patients at
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago Medicine, IL.
- Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
- Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Institute of Women and Children's Health, Department of Women and Children's Health, School of Life Course and Population Sciences, King's College London, London, United Kingdom.
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago Medicine, IL. Electronic address: srana@bsd.uchicago.edu.
Förderung
- Siemens
- Beckman Coulter Foundation
- Roche
Zitieren
APA
Suresh, S., Patel, E., Mueller, A., Morgan, J., Lewandowski, W. L., Verlohren, S., von Dadelszen, P., Magee, L. A., & Rana, S. (2023). The additive role of angiogenic markers for women with confirmed preeclampsia. American Journal of Obstetrics and Gynecology, 228(5), 573.e1-573.e11. https://doi.org/10.1016/j.ajog.2022.10.044
Vancouver
Suresh S, Patel E, Mueller A, Morgan J, Lewandowski WL, Verlohren S, et al. The additive role of angiogenic markers for women with confirmed preeclampsia. American Journal of Obstetrics and Gynecology. 2023;228(5):573.e1-573.e11. doi:10.1016/j.ajog.2022.10.044
BibTeX
@article{Suresh2023,
author = {Suresh, Sunitha and Patel, Easha and Mueller, Ariel and Morgan, Jessica and Lewandowski, Whitney Lynn and Verlohren, Stefan and von Dadelszen, Peter and Magee, Laura A and Rana, Sarosh},
title = {The additive role of angiogenic markers for women with confirmed preeclampsia},
journal = {American Journal of Obstetrics and Gynecology},
year = {2023},
volume = {228},
number = {5},
pages = {573.e1--573.e11},
doi = {10.1016/j.ajog.2022.10.044}
}
EUVIMED